12:00 AM
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Clolar clofarabine regulatory update

FDA's Oncologic Drugs Advisory Committee voted 9-3 that randomized, controlled testing would be needed to establish the efficacy and safety of Genzyme's Clolar clofarabine. The company is seeking regular or accelerated approval of second-generation purine nucleoside analog...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >